Impact of Voglibose on of Metabolic Control Indicators in Patients with Diabetes Mellitus Type 1

V.I. Pankiv

Abstract


New therapeutic options to control diabetes mellitus (DM) emerged with the discovery of alpha-glucosidase inhibitors which slow the absorption of carbohydrates in the small intestine. The objective of the study — to investigate the effect of voglibose administration on parameters of glycemic control, lipid metabolism and tolerability in patients with DM type 1. Materials and Methods. Criteria for inclusion in the study: DM type 1, age from 26 to 48 years, the level of glycated hemoglobin (HbA1c) from 8 to 9 %. 19 patients were examined (7 men and 12 women, mean age 37.2 ± ± 3.9 years, DM duration 8.5 ± 1.4 years. Results. During the follow-up period (12 weeks), the level of HbA1c significantly decreased from 9.4 ± 0.6 % to 7.8 ± 0.4 % (p < 0.05). On the background of additional administration of voglibose, we observed a significant reduction in fasting glucose level from 10.37 ± 0.36 mmol/l to 7.39 ± 0.28 mmol/l (p < 0.01) and postprandial — from 12.29 ± 1.42 mmol/l to 8.46 ± 0.64 mmol/l (p < 0.01). At that, we have noted a significant reduction of total cholesterol (from 5.83 ± 0.11 mmol/l to 5.38 ± 0.08 mmol/l, p < 0.05), triglycerides (from 1.82 ± 0.03 mmol/l to 1.46 ± 0.03 mmol/l, p < 0.05) and low-density lipoprotein cholesterol (from 3.41 ± 0.05 mmol/l to 3.37 ± ± 0.04 mmol/l, p < 0.05). There were no significant changes in high-density lipoprotein cholesterol parameters. In two surveyed persons, we have detected adverse effects (bloating), which did not require discontinuation of therapy. Conclusion. Additional administration of voglibose at a dose of 0.9 mg/day on a background of insulin therapy helps to improve glycemic control and lipid metabolism, to reduce the daily dose of exogenous insulin and hypoglycemic reactions incidence in patients with DM type 1.


Keywords


diabetes mellitus type 1; glycemic control; voglibose

References


Полторак В.В., Горшунська М.Ю., Красова Н.С. Адипонектин та цукровий діабет 2-го типу (патогенетичні аспекти як підґрунтя для оптимізації антидіабетичної фармакотерапії) [Текст] / В.В. Полторак // Международный эндокринологический журнал. — 2014. — № 5 (61). — С. 95-104.

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Research Group // N. Engl. J. Med. — 2000. — 342(6). — 381-9.

Silva F.M. Fiber intake and glycemic control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials / F.M. Silva, C.K. Kramer, J.C. de Almeida et al. // Nutr. Rev. — 2013. — Vol. 71, № 12. — P. 790-801. doi: 10.1111/nure.12076. Epub 2013 Nov 1.

Kumar R.V., Sinha V.R. Newer insights into the drug delivery approaches of α-glucosidase inhibitors. // Expert. Opin. Drug. Deliv. — 2012. — Vol. 9(4). — P. 403-416.

Chen X., Zheng Y., Shen Y. Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors // Curr. Med. Chem. — 2006. — 13(1). — 109-16.

Dimitriadis G., Karaiskos C., Raptis S. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus // Horm. Metab. Res. — 1986. — 18. — 253-5.

Spengler M., Schmitz H., Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study // Clin. Drug. Investig. — 2005. — 25. — 651-9.

American Diabetes Association Standards of medical care in diabetes 2015 // The Journal of Clinical and Applied Research and Education. — 2015. — Vol. 38, Suppl. 1. — P. 1-94.

Thurston M.M., Galdo J.A., Bourg C.A. Clinical considerations for insulin pharmacotherapy in ambulatory care: review of primary literature and an evidence-based approach for treatment // Clinical Diabetes. — 2015. — Vol. 33. — P. 20-27.

Hollander P., Pi-Sunyer X., Coniff R.F. Acarbose in the treatment of type I diabetes // Diabetes Care. — 1997. — 20. — 248-53.

Spengler M., Schmitz H., Landen H. Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus: a postmarketing surveillance study // Clin. Drug. Investig. — 2005. — 25. — 651-9.

Jefferies C.A., Hamilton J., Daneman D. Potential adjunctive therapies in adolescents with type 1 diabetes mellitus // Treat. Endocrinol. — 2004. — 3. — 337-43.

Marena S., Tagliaferro V., Cavallero G. et al. Double-blind crossover study of acarbose in type 1 diabetic patients // Diabet. Med. — 1991. — 8. — 674-8.

Sels J.P., Verdonk H.E., Wolffenbuttel B.H. Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicentre study // Diabetes Res. Clin. Pract. — 1998. — 41. — 139-45.




DOI: https://doi.org/10.22141/2224-0721.1.65.2015.75889

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru